Compare SSP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSP | AKBA |
|---|---|---|
| Founded | 1878 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.6M | 251.0M |
| IPO Year | 1998 | 2014 |
| Metric | SSP | AKBA |
|---|---|---|
| Price | $2.75 | $1.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $6.95 | $4.67 |
| AVG Volume (30 Days) | 574.7K | ★ 5.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,150,585,000.00 | N/A |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.04 | $0.82 |
| 52 Week High | $5.39 | $4.08 |
| Indicator | SSP | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 48.17 |
| Support Level | $2.73 | $0.85 |
| Resistance Level | $3.01 | $1.56 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 21.37 | 74.74 |
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.